AACR 2024: Apr 7-10
We are excited to be attending the American Association of Cancer Research (AACR) 2024 annual conference from April 5-10 in San Diego, California! Set up a visit with our team at Booth 939, which will be open from April 7-10, and stop by our 20 posters, which can now be added to your AACR itinerary.
AACR 2024 Poster Presentations
|
Poster Title |
Poster Number |
Date & Time |
Location |
Poster Board Number |
BioMice |
Development of humanized VEGFA models to assess preclinical efficacy of novel therapeutics in vivo |
125 |
Apr 7, 1:30 PM – 5:00 PM |
Section 4 |
29 |
Validation of humanized TL1A mice for advancing preclinical research |
124 |
Apr 7, 1:30 PM – 5:00 PM |
Section 4 |
28 |
Establishment of humanized CD3EDG/4-1BB mice for testing novel T cell engagers |
123 |
Apr 7, 1:30 PM – 5:00 PM |
Section 4 |
27 |
Generation and validation of a novel humanized IL-31/IL-31RA/OSM/OSMR mouse model |
113 |
Apr 7, 1:30 PM – 5:00 PM |
Section 4 |
17 |
Generation of humanized PD-1/PD-L1/CD94/NKG2A mice for evaluating novel combination therapies |
116 |
Apr 7, 1:30 PM – 5:00 PM |
Section 4 |
20 |
TIL analysis demonstrates different mechanisms underlying PD-1 resistance in animal models |
1531 |
Apr 8, 9:00 AM – 12:30 PM |
Section 9 |
18 |
Establishment of a humanized IL5/IL5RA mouse model to evaluate modulators of eosinophilic inflammation in vivo |
5339 |
Apr 9, 1:30 PM – 5:00 PM |
Section 4 |
19 |
A novel humanized NKP46 mouse model to support xenograft studies evaluating NK cell-based cancer immunotherapies |
LB363 |
Apr 9, 1:30 PM – 5:00 PM |
Section 53 |
12 |
Generation of a novel severely immunodeficient Sprague Dawley rat model for xenograft studies |
LB365 |
Apr 9, 1:30 PM – 5:00 PM |
Section 53 |
14 |
Development and validation of humanized HLA mouse model platforms for preclinical evaluation of novel peptide vaccines |
5345 |
Apr 9, 1:30 PM – 5:00 PM |
Section 4 |
25 |
A novel humanized CD16A model to evaluate efficacy of human antibody therapeutics in triggering ADCC |
5346 |
Apr 9, 1:30 PM – 5:00 PM |
Section 4 |
26 |
RenBiologics
|
Identification of fully human CCR8 antibodies that demonstrate excellent ADCC function, potent blocking activity, and robust anti-tumor immune responses |
LB130 |
Apr 8, 9:00 AM – 12:30 PM |
Section 52 |
18 |
A first-in-class bispecific ADC targeting FOLR1 and MUC1 exhibits promising anti-tumor activity in a FOLR1low xenograft model |
LB127 |
Apr 8, 9:00 AM – 12:30 PM |
Section 52 |
15 |
BCG020, a novel bispecific antibody targeting EGFR and CD70, is effective against EGFR and CD70 high expressed tumors |
2724 |
Apr 8, 1:30 PM – 5:00 PM |
Section 6 |
15 |
A novel EGFR×HER3-targeting bispecific antibody drug-conjugate, BCG019, demonstrates robust anti-tumor efficacy in preclinical evaluation |
2619 |
Apr 8, 1:30 PM – 5:00 PM |
Section 2 |
22 |
BCG016, a first-in-class bispecific antibody-drug conjugate targeting 5T4 and MUC1, demonstrates potent preclinical anti-tumor activity |
2620 |
Apr 8, 1:30 PM – 5:00 PM |
Section 2 |
23 |
BCG033, a novel bispecific antibody-drug conjugate targeting PTK7 and TROP2, demonstrates preclinical efficacy against triple-negative breast cancer and other solid tumor xenografts |
2616 |
Apr 8, 1:30 PM – 5:00 PM |
Section 2 |
19 |
BCG017, a bispecific ADC targeting PTK7 and EGFR exhibits anti-tumor efficacy in PDX models |
2618 |
Apr 8, 1:30 PM – 5:00 PM |
Section 2 |
21 |
BCG022, a novel HER3×MET bispecific antibody-drug conjugate (bsADC), demonstrates promising anti-tumor efficacy |
2617 |
Apr 8, 1:30 PM – 5:00 PM |
Section 2 |
20 |
Targeting mutant KRAS proteins with novel TCR-mimic fully human antibodies |
6717 |
Apr 10, 9:00 AM – 12:30 PM |
Section 3 |
15 |
Set Up Meetings & Secure Your Swag Bag!
We’re excited to connect with you at our posters and booth for 1:1 meetings. Use our event signup form on the left side of this page to secure your Biocytogen swag bag online, and the meeting link below to reserve a time to engage with our experts. Don’t miss out on the opportunity to receive our new swag items showcasing our sub-brands.
Limited availability, so grab yours before they’re gone!
The AACR Annual Meeting is the focal point of the cancer research community, where scientists, clinicians, other health care professionals, survivors, patients, and advocates gather to share the latest advances in cancer science and medicine. From population science and prevention; to cancer biology, translational, and clinical studies; to survivorship and advocacy; the AACR Annual Meeting highlights the work of the best minds in cancer research from institutions all over the world. (Source: AACR)
Event Date: April 7-10, 2024 | Event Location: San Diego, CA